Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Tofacitinib for ulcerative colitis

Study shows real-world evidence for efficacy and safety

    • Congress Reports
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • RX
    • Studies
  • 3 minute read

The prevalence of ulcerative colitis (CU) in Switzerland is 1/500. The JAK inhibitor tofacitinib has been an arrow in the treatment quiver since 2019. In the phase 3 OCTAVE study, it proved to be effective in achieving and maintaining clinical and endoscopic remission compared to placebo. In the real world, however, the data situation in Switzerland has so far been inadequate. A study group has now addressed this issue.

The aim of the post-marketing study FACES (First Tofacitinib Experience in Switzerland) was to assess the efficacy and safety of tofacitinib in the treatment of adults with moderate to severe ulcerative colitis in Switzerland under real-world conditions. In accordance with the OCTAVE study design, the research group assessed clinical and endoscopic activity at baseline and at weeks 8, 26 and 52 using the Mayo score, as explained by Prof. Dr. Alain Schoepfer, Department of Gastroenterology and Hepatology, Lausanne University Hospital, and member of the FACES survey group [1]. Tofacitinib was administered 2× 10 mg per day during the 8-week induction phase and 2× 5 mg during the maintenance phase.

In the Mayo scoring system, the factors stool frequency, rectal bleeding, endoscopy findings and the physician’s overall assessment are taken into account to evaluate the activity of CU. Each of these four components is rated individually from 0 to 3, resulting in a total score of 0 to 12.

Significant decline in Mayo score

The researchers included 104 adults in their study (mean age 41 ± 14.4 years, median duration of illness 6 years, IQR 3- 11, range 1-44 years, 48.1% women). The patients’ diseases were localized:

  • Proctitis 3.9%,
  • left-sided colitis 34.6%,
  • extensive colitis 11.5%,
  • Pancreatitis 50%.

All participants had received mesalazine, topical budesonide and prednisone during pre-treatment, 70.2% also received azathioprine. Before starting tofacitinib therapy, the patients had undergone a median of 2 unsuccessful biologic treatments (mainly infliximab and vedolizumab (79% and 62% respectively), as well as golimumab (23%), adalimumab, ustekinumab (20% each) and tacrolimus (15%); IQR 1-3, range 0-6). 21 subjects (20.2%) were also given prednisone at the start of treatment with tofacitinib. Over time, a significant decrease in the Mayo score was observed (Table 1) .

At week 8, adherence to tofacitinib was still 100%. After 26 weeks, 77 of the 104 patients (74%) remained adherent; after one year, 63/104 (60.6%) were still adherent. No deep vein thrombosis, pulmonary embolism, serious advanced cardiovascular events or neoplasia were observed. Herpes zoster reactivation occurred in four patients during the induction phase and in two during the maintenance phase.

In terms of stool frequency, all patients had at least three more bowel movements than normal at baseline. After 52 weeks, this could be reduced to a normal level or a maximum of 1-2 bowel movements more in almost all patients (Fig. 1).

In this Swiss CU population, which was characterized by a complicated disease course and multiple failures of biologic therapies, more than 60% were still on tofacitinib at week 52 as they continued to have clinical benefit, Prof. Schoepfer concluded. With a favorable safety profile, no patient was treated simultaneously with systemic steroids in weeks 26 and 52.

Congress: SGG Annual Congress 2023

Source:

  1. Schoepfer A: Presentation “Real-life efficacy and safety of tofacitinib to treat moderate-to-severe ulcerative colitis in Switzerland”; Annual Congress of the Swiss Society of Gastroenterology (SGG), Interlaken, 14.09.2023.

GASTROENTEROLOGY PRACTICE 2023: 1(2): 31 (published 27.11.23, ahead of print)

Autoren
  • Jens Dehn
Publikation
  • GASTROENTEROLOGIE PRAXIS
Related Topics
  • clinical remission
  • CU
  • Endoscopic remission
  • JAK Inhibitors
  • mayo score
  • Tofacitinib
  • Ulcerative colitis
Previous Article
  • Study report: Primary cutaneous lymphomas

Skin-directed or systemic therapy?

  • Congress Reports
  • Dermatology and venereology
  • Oncology
  • RX
  • Studies
View Post
Next Article
  • ESC update for SGLT-2-i

Heart failure patients benefit regardless of LVEF

  • Cardiology
  • Congress Reports
  • General Internal Medicine
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 8 min
  • Efficacy, mechanism of action and clinical effects

Garlic and high blood pressure

    • Cardiology
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
View Post
  • 9 min
  • Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)

Diagnosis at an early stage, prognostic classifications and outlook

    • Cardiology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Case report: Drug-induced hepatitis

Rare side effect of tirzepatide therapy

    • Cases
    • Education
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 4 min
  • Plea for sex-specific neurology

Migraine in men: underdiagnosed, underestimated, under-researched

    • Education
    • Neurology
    • RX
    • Studies
View Post
  • 4 min
  • Prurigo nodularis

Retrospective analyses of large data sets from everyday practice

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.